Skip to main navigation Skip to search Skip to main content

Subasumstat, a first-in-class inhibitor of SUMO-activating enzyme, demonstrates dose-dependent target engagement and SUMOylation inhibition, leading to rapid activation of innate and adaptive immune responses in the dose escalation portion of a phase 1/2 clinical study

  • G. Saggu
  • , D. Stroopinsky
  • , A. Z. Dudek
  • , A. J. Olszanski
  • , D. Juric
  • , A. Dowlati
  • , U. Vaishampayan
  • , H. Assad
  • , J. Rodón
  • , J. Gibbs
  • , J. Green
  • , Z. Du
  • , R. Rudicell
  • , K. Kannan
  • , R. Gharavi
  • , A. Gomez-Pinillos
  • , R. J. Fram
  • , A. Berger
  • , K. Sachsenmeier
  • , S. Kasar
  • Translational Oncology
  • Oncology Therapeutic Area OTAU
  • Regions Hospital
  • Harvard University
  • Case Western Reserve University
  • University of Michigan, Ann Arbor
  • Wayne State University
  • University of Texas MD Anderson Cancer Center
  • Quantitative Clinical Pharmacology
  • Clinical Biomarker Innovation and Development
  • Computational Biology
  • Precision and Translational Medicine
  • Oncology Therapeutic Area Unit
  • Oncology Clinical Research
  • Clinical Science OTAU R&D
  • Oncology Precision and Translational Medicine

Research output: Contribution to journal › Article › peer-review

6 Scopus citations

Fingerprint

Dive into the research topics of 'Subasumstat, a first-in-class inhibitor of SUMO-activating enzyme, demonstrates dose-dependent target engagement and SUMOylation inhibition, leading to rapid activation of innate and adaptive immune responses in the dose escalation portion of a phase 1/2 clinical study'. Together they form a unique fingerprint.
Sort by

Pharmacology, Toxicology and Pharmaceutical Science

Immunology and Microbiology